Angiotensin Ii

Angiotensin Ii

SCHEMBL513519

CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1

The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
AGTR1 known ✓ P30556 3/20 0.82
AGTR2 P50052 9/20 0.82
REN P00797 3/20 0.64
LNPEP Q9UIQ6 3/20 0.62
NPY1R P25929 1/20 0.61
NPY2R P49146 1/20 0.61
NPY4R P50391 1/20 0.61
NPY5R Q15761 1/20 0.61
ANPEP P15144 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Angiotensin Ii SCHEMBL13232382 0.98 AGTR2 (0.84) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL1189 0.98 AGTR2 (0.84) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL2566771 0.98 AGTR2 (0.84) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL3465991 0.98 AGTR2 (0.83) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL21267957 0.98 AGTR2 (0.83) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL14990505 0.98 AGTR2 (0.83) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL8898391 0.98 AGTR2 (0.83) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL1585377 0.98 AGTR2 (0.83) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL2183118 0.98 AGTR2 (0.83) AGTR2AGTR1RENLNPEPANPEP
Angiotensin Ii SCHEMBL21408200 0.97 AGTR2 (0.82) AGTR2AGTR1RENLNPEPANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1104305-B1 USE OF ANGIOTENSIN IN THE TREATMENT OF CANCER METASTASIS QUEEN MARY & WESTFIELD COLLEGE (GB) 2005-03-23 EP claimed
CN-115969981-A Application of beta 3-adrenoceptor agonist in preparation of medicine for preventing or/and treating abdominal aortic aneurysm 中山大学孙逸仙纪念医院 2023-04-18 CN disclosed
EP-3525778-A1 COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS Bayer Pharma Aktiengesellschaft (DE) 2019-08-21 EP disclosed
EP-3525779-A1 COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS Bayer Pharma Aktiengesellschaft (DE) 2019-08-21 EP disclosed
US-9048195-B2 Polishing fluid and polishing method FUJIFILM CORPORATION (JP) 2015-06-02 US disclosed
US-20130164341-A1 PREPARATION OF FORMULATIONS OF ANGIOTENSIN II AT1 RECEPTORS ANTAGONISTS FOR THE TREATMENT OF ARTERIAL HYPERTENSION, OTHER CARDIOVASCULAR ILLNESSES AND ITS COMPLICATIONS UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) 2013-06-27 US disclosed
US-8293723-B2 Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) 2012-10-23 US disclosed
US-20120028467-A1 POLISHING FLUID AND POLISHING METHOD FUJIFILM CORPORATION (JP) 2012-02-02 US disclosed
US-20110091541-A1 Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) 2011-04-21 US disclosed
US-7858597-B2 Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications UNIVERSIDADE FEDERAL DE MIMAS GERAIS - UFMG (BR) 2010-12-28 US disclosed
CN-1523985-B Preparation of formulations of angiotensin IIAT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications UNIV MINAS GERAIS 2010-05-12 CN disclosed
US-20080108575-A1 Preparation of formulations of angiotensin II AT1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications MILLAN RUBEN D S 2008-05-08 US disclosed
US-20040171584-A1 Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG (BR) 2004-09-02 US disclosed
CN-1523985-A Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications �Ϻ���ͨ��ѧ 2004-08-25 CN disclosed
EP-1389106-A1 PREPARATION OF FORMULATIONS OF ANGIOTENSIN II AT1 RECEPTORS ANTAGONISTS FOR THE TREATMENT OF ARTERIAL HYPERTENSION, OTHER CARDIOVASCULAR ILLNESSES AND ITS COMPLICATIONS Universidade Federal de Minas Gerais-Ufmg (BR) 2004-02-18 EP disclosed
WO-2002080910-A1 PREPARATION OF FORMULATIONS OF ANGIOTENSIN II AT1 RECEPTORS ANTAGONISTS FOR THE TREATMENT OF ARTERIAL HYPERTENSION, OTHER CARDIOVASCULAR ILLNESSES AND ITS COMPLICATIONS UNIVERSIDADE FEDERAL DE MINAS GERAIS-UFMG (BR) 2002-10-17 WO disclosed
WO-1995011894-A1 HISTAMINE H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF THE UNIVERSITY OF TOLEDO (US) 1995-05-04 WO disclosed
EP-0095584-B1 SUBSTITUTED 4-PHENOXY AND 4-PHENYLTHIO PROLINES E.R. Squibb & Sons, Inc. (US) 1987-01-07 EP disclosed
US-4242265-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1980-12-30 US disclosed